Evidence map›Paper›PMID 23948603›Full record

ArticleBiochimica et biophysica acta2013

Serum regulation of Id1 expression by a BMP pathway and BMP responsive element.

Thera C Lewis, Ron Prywes

Open access · greenAbstract read
In one paragraph

Article in Biochimica et biophysica acta, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.1field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. The target landscape of clinical kinase drugs.Science (New York, N.Y.) · 2017
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Thera C LewisDepartment of Biological Sciences, Columbia University, New York, NY 10027, USA. Electronic address: Tca2103@columbia.edu.
Ron Prywes
Columbia University · US

Funding

Transcriptional regulation of c-fos and immediate early genesR01CA050329 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI PRYWES, RON M · 1989 to 2009
$3.3M
NCI NIH HHS CA50329NCI NIH HHS R01 CA050329
6 · The paper itself

Abstract

Immediate early genes (IEGs) are expressed upon re-entry of quiescent cells into the cell cycle following serum stimulation. These genes are involved in growth control and differentiation and hence their expression is tightly controlled. Many IEGs are regulated through Serum Response Elements (SREs) in their promoters, which bind Serum Response Factor (SRF). However, many other IEGs do not have SREs in their promoters and their serum regulation is poorly understood. We have identified SRF-independent IEGs in SRF-depleted fibroblasts. One of these, Id1, was examined more closely. We mapped a serum responsive element in the Id1 promoter and find that it is identical to a BMP responsive element (BRE). The Id1 BRE is necessary and sufficient for the serum regulation of Id1. Inhibition of the BMP pathway by siRNA depletion of Smad 4, treatment with the BMP antagonist noggin, or the BMP receptor inhibitor dorsomorphin blocked serum induction of Id1. Further, BMP2 is sufficient to induce Id1 expression. Given reports that SRC inhibitors can block Id1 expression, we tested the SRC inhibitor, AZD0530, and found that it inhibits the serum activation of Id1. Surprisingly, this inhibition is independent of SRC or its family members. Rather, we show that AZD0530 directly inhibits the BMP type I receptors. Serum induction of the Id1 related gene Id3 also required the BMP pathway. Given these and other findings we conclude that the Id family of IEGs is regulated by BMPs in serum through similar BREs. This represents a second pathway for serum regulation of IEGs.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsAntineoplastic AgentsBenzodioxolesBlotting, WesternBone Morphogenetic Protein ReceptorsBone Morphogenetic ProteinsCells, CulturedColonic NeoplasmsHumansInhibitor of Differentiation Protein 1LuciferasesMiceNIH 3T3 CellsPromoter Regions, GeneticQuinazolinesAntineoplastic AgentsBenzodioxolesBone Morphogenetic Protein ReceptorsBone Morphogenetic ProteinsInhibitor of Differentiation Protein 1LuciferasesQuinazolinesRNA, MessengerRNA, Small InterferingsaracatinibSmad Proteinssrc-Family KinasesAZD0530, saracatinibBMP Response ElementId1, inhibitor of DNA binding/differentiation 1Immediate early geneSerum Response Element

Identifiers

PMID23948603
PMCPMC3786144
OpenAlexW1997915808

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.